|
 |
Prekinis pavadinimas |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Acetaflur |
Meksikas |
|
Asoleudox |
Meksikas |
|
Beneflur |
Ispanija, Meksikas |
|
Fludabin |
Peru |
|
Fludacel |
Indija, Peru |
|
Fludakebir |
Peru |
|
Fludalym |
Turkija |
|
Fludara |
Airija, Austrija, Belgija, Čilė, Danija, Didžioji Britanija, Egiptas, Indija, Iranas, Italija, Jungtinės Amerikos Valstijos, Kolumbija, Lenkija, Liuksemburgas, Malaizija, Naujojoje Zelandijoje, Olandija, Portugalija, Prancūzija, Rumunija, Saudo Arabija, Suomija, Švedija, Šveicarija, Venesuela, Vengrija, Vokietija |
|
Fludarabin |
Islandija, Italija, Norvegija, Švedija, Šveicarija |
|
Fludarabina |
Argentina, Ispanija, Kolumbija, Peru, Rumunija |
|
Fludarabine |
Belgija, Iranas, Jungtinės Amerikos Valstijos, Kanada, Naujojoje Zelandijoje, Norvegija, Šveicarija |
|
Fludarin |
Indija |
|
Fludarosa |
Argentina |
|
Forclina |
Peru |
|
Ludabina |
Čilė, Kolumbija |
|
Mepredin |
Peru |
|
Naprobin |
Indija |
|
Neoflubin |
Iranas |
|
|
 |
 |
Bibliografija : Fludarabine phosphate |
|
|
tipas |
leidinys |
| 3 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Žurnalas |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Žurnalas |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 492 |
Žurnalas |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Žurnalas |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
Žurnalas |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
Žurnalas |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 3306 |
Žurnalas |
Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2. |
| 3595 |
Laboratorija |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3604 |
Laboratorija |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3637 |
Laboratorija |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3644 |
Laboratorija |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3670 |
Žurnalas |
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30. |
| 3838 |
Laboratorija |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4398 |
Žurnalas |
Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020 |
| 4964 |
Laboratorija |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit.
B BRAUN MELSUNGEN AG 2019 |
|
|
